Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Diabetes & Endocrinology

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Cardiology

Show all topics

DOI

10.1016/s2213-8587(19)30158-5

Other Formats

PDF